United Therapeutics (UTHR) has attracted investor attention after recent share price moves, with the stock showing an 8.9% return over the past month and 21.8% over the past 3 months.

At a share price of $569.11, United Therapeutics has paired an 8.9% 1 month share price return with a 1 year total shareholder return of 89.2%. Recent momentum has been building on already solid longer term gains.

If you are comparing United Therapeutics with other potential opportunities in healthcare, this is a good moment to scan for more specialized names through our screener of 32 healthcare AI stocks

With United Therapeutics trading at $569.11, an intrinsic discount flag, a value score of 4 and a price target implying a 13.3% gap, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 11.6% Undervalued

At $569.11, the most followed narrative around United Therapeutics points to a fair value of $644.08, framing the recent share price strength in a valuation gap context.

The TETON-1 readout in idiopathic pulmonary fibrosis is viewed as a key value driver, with some bullish analysts framing United Therapeutics as a top pick tied to this program and pointing to potential upside in fair value if further data and approvals align with expectations.

Curious what justifies that higher fair value. The narrative leans on ambitious revenue targets, firm profit margins and a future earnings multiple that assumes meaningful clinical and commercial follow through.

Result: Fair Value of $644.08 (UNDERVALUED)

However, this hinges on clinical and commercial execution, with trial setbacks or pricing pressure on key PAH therapies capable of quickly challenging those upbeat assumptions.

Another View: What Earnings Multiples Are Saying

While the narrative fair value points to 11.6% upside, the current P/E of 18.7x tells a more cautious story. It sits above the US Biotechs industry at 17.3x, yet below a fair ratio estimate of 23.2x and well under peer levels around 44.2x, which hints at both valuation risk and potential opportunity.

In practice, that means you are paying a higher price than the sector average for United Therapeutics' earnings today, but not as much as similar peers or the fair ratio suggest the market could move towards over time. The key question is which of those anchors you trust most when deciding how much optimism is already in the price.

Next Steps

The mixed signals on valuation and growth may leave you unsure. Do not wait around; review the data yourself and weigh the potential 3 key rewards

Looking for more investment ideas?

If United Therapeutics has caught your eye, it is worth widening your search, comparing different return profiles, balance sheet strengths and dividend approaches across a broader set of stocks.

• Target potential value opportunities before others do by scanning our list of 53 high quality undervalued stocks.
• Protect your capital with companies that prioritise resilience by focusing on the 72 resilient stocks with low risk scores.
• Spot under the radar names that still fly below most screens by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.